These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Radionuclide Therapy for Neuroendocrine Tumors. Cives M; Strosberg J Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446 [TBL] [Abstract][Full Text] [Related]
24. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Toumpanakis C; Caplin ME Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113 [TBL] [Abstract][Full Text] [Related]
28. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166 [TBL] [Abstract][Full Text] [Related]
29. Gastroenteropancreatic Neuroendocrine Tumors. Cives M; Strosberg JR CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930 [TBL] [Abstract][Full Text] [Related]
30. Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023. di Santo G; Santo G; Sviridenko A; Virgolini I Theranostics; 2024; 14(3):940-953. PubMed ID: 38250038 [TBL] [Abstract][Full Text] [Related]
32. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Sorbye H; Kong G; Grozinsky-Glasberg S Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429 [TBL] [Abstract][Full Text] [Related]
33. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154 [TBL] [Abstract][Full Text] [Related]
34. Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial. Zhang P; Shi S; Xu J; Chen Z; Song L; Zhang X; Cheng Y; Zhang Y; Ye F; Li Z; Yin F; Ji D; Gao H; Li Y; Chen W; Yang M; Weng D; Wu C; Ma Y; Sheng W; Zhao Y; Yin X; Shen W; Su W; Shi M; Fan S; Tan P; Xu Q; Lu M; Shen L Eur J Cancer; 2024 Mar; 199():113539. PubMed ID: 38237373 [TBL] [Abstract][Full Text] [Related]
35. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective. Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203 [TBL] [Abstract][Full Text] [Related]
36. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Grillo F; Florio T; Ferraù F; Kara E; Fanciulli G; Faggiano A; Colao A; Endocr Relat Cancer; 2018 Sep; 25(9):R453-R466. PubMed ID: 29769293 [TBL] [Abstract][Full Text] [Related]
37. Combination Systemic Therapies in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Comprehensive Review of Clinical Trials and Prospective Studies. Diamantopoulos LN; Kalligeros M; Halfdanarson TR; Diamantis N; Toumpanakis C Biology (Basel); 2023 Jul; 12(8):. PubMed ID: 37626955 [TBL] [Abstract][Full Text] [Related]
39. Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs. Wanting H; Jian Z; Chaoxin X; Cheng Y; Chengjian Z; Lin Z; Dan C J Cancer Res Clin Oncol; 2023 Aug; 149(9):5975-5987. PubMed ID: 36609710 [TBL] [Abstract][Full Text] [Related]